price month
under-perform neutral
 close
upgrad neutral deal
move neutral propos acquisit upgrad abax neutral
under-perform
acquisit compani earlier today rais tp
ep expect success deal complet
detail abax deal expedit ztss presenc companion anim
diagnost one fastest grow segment anim health grow
healthi sustain high-singl digit pace annual repres
market opportun abl leverag unmatch global
sale presenc reinvigor growth abax abax trajectori
admittedli less consist late base proprietari us
veterinari survey work abax share ttm averag term
despit address veterinari practic dogs/cat
intern diagnost spend remain low sizeabl ou market
treatment paradigm vari
consider across geographi expect ou diagnost util
expand particularli leverag broader global presenc
acquisit synbiot aug acquir
manufactur specialti instrument consum veterinari poc
diagnost abax alongsid previou dognost effort
compet directli alongsid industri leader idexx laboratori
outperform well smaller player rate
view ztss share ep trade well industri
peer valuat fulli reflect opportun
innov oper improv contribut capit deploy
initi statu industri leader robust dynam sector
risk includ failur deal close
valuat metric
number share
suiss seek busi compani cover research report result investor awar
firm may conflict interest could affect object report investor consid report
singl factor make invest decis
abax lead manufactur point-of-car diagnost
equip particip anim human health care
set develop portabl blood instrument rapidli measur
blood constitu clinician offic set
price may rate under-perform neutral target price analyst erin
profit tax
chang work capit
flow oper
free cash-flow firm
flow invest
cash-flow financ activ
chang net cash/debt
total liabil equiti
share wtd average
price book
roe stated-return
 close
blue sky valuat base expect
success complet zoeti acquisit abax
grey sky valuat assum increasingli
continu difficulti distribut relationship meaning
contribut new product launch unexpect weak
broader industri demand
compani mention price
